title: Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy.
abstract: Tumor hypoxia, either preexisting or as a result of oxygen depletion during photodynamic therapy (PDT) light irradiation, can significantly reduce the effectiveness of PDT-induced cell killing. To overcome tumor hypoxia and improve tumor cell killing, we propose using supplemental hyperoxygenation during Photofrin-PDT. The mechanism for the tumor cure enhancement of the hyperoxygenation-PDT combination is investigated using an in vivo-in vitro technique. A hypoxic tumor model was established by implanting mammary adenocarcinoma in the hind legs of mice. Light irradiation (200 J/cm2 at either 75 or 150 mW/cm2), under various oxygen supplemental conditions (room air, carbogen, 100% normobaric or hyperbaric oxygen), was delivered to animals that received 12.5 mg/kg Photofrin 24 h before light irradiation. Tumors were harvested at various time points after PDT and grown in vitro for colony formation analysis. Treated tumors were also analyzed histologically. The results show that when PDT is combined with hyperoxygenation, the hypoxic condition could be improved and the cell killing rate at various time points after PDT could be significantly enhanced over that without hyperoxygenation, suggesting an enhanced direct and indirect cell killing associated with high-concentration oxygen breathing. This study further confirms our earlier observation that when a PDT treatment is combined with hyperoxygenation it can be more effective in controlling hypoxic tumors.
authors.affiliation: Research and Development, HealthONE Alliance, Denver, CO 80203, USA. zheng_huang@msn.com
authors.forename: Zheng
authors.initials: Z
authors.lastname: Huang
authors.forename: Qun
authors.initials: Q
authors.lastname: Chen
authors.forename: Abdus
authors.initials: A
authors.lastname: Shakil
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
authors.forename: Jill
authors.initials: J
authors.lastname: Beckers
authors.forename: Howard
authors.initials: H
authors.lastname: Shapiro
authors.forename: Fred W
authors.initials: FW
authors.lastname: Hetzel
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D017323:Dihematoporphyrin Ether / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D010100:Oxygen / Q000008:administration & dosage*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*
chemical_list: D017319:Photosensitizing Agents; D017323:Dihematoporphyrin Ether; D010100:Oxygen